Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03529825|
Recruitment Status : Recruiting
First Posted : May 18, 2018
Last Update Posted : September 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Microbial Colonization||Drug: Rifaximin||Early Phase 1|
This study is for patients who will be having a blood/marrow transplant (BMT) to treat leukemia, lymphoma or other cancer of the blood. The blood or marrow cells will come from another person (donor)—allogeneic BMT. Bacterial infections and acute graft versus host disease (AGVHD) are frequent complications of allogeneic BMT. Bacterial infections sometimes happen because injury to the gut during transplant allows gut bacteria to cross the injured gut barrier and get to the blood. AGVHD happens when certain white blood cells, called T-cells, in the donor cells (the graft) attack the patient's body.
Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Pilot, single arm prospective study with retrospective control arm|
|Masking:||None (Open Label)|
|Official Title:||Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation|
|Actual Study Start Date :||July 18, 2018|
|Estimated Primary Completion Date :||May 2020|
|Estimated Study Completion Date :||May 2020|
Rifaximin will be administered twice a day orally or by nasogastric tube to patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
No Intervention: Retrospective comparison cohort
Thirty six patients who underwent HSCT for hematologic malignancies, and received myeloablative conditioning, without prophylactic antibiotics, between 2013-2017 enrolled in the Aflac biorepository will comprise the comparison arm. Clinical data on transplant and infection characteristics is available and linked to stool microbiome samples already analyzed and described. Stored plasma and peripheral blood mononuclear cells are available for further analysis.
- Alterations to microbiome diversity in children treated with rifaximin compared to the historical cohort. [ Time Frame: Period between the start of the preparative regimen and day 28 post transplant ]Composition will be assessed using 16S RNA sequencing. The Shannon index will be calculated for quantification of bacterial diversity.
- Rates of BSI pathogen infection/colonization frequency during the treatment period compared to the historical cohort. [ Time Frame: Period between the start of the preparative regimen and day 28 post transplant ]Results of the GI pathogen panel, a test incorporated into routine patient care detecting DNA or RNA of 22 common viral, bacterial, and parasitic organisms, will provide a second assessment through molecular detection of the presence of common organisms associated with intestinal dysbiosis.
- Transplant related mortality (TRM) [ Time Frame: Period between the start of the preparative regimen and day 28 post transplant ]Number of deaths occurring in continuous complete remission.
- Number of patients with Acute GVHD [ Time Frame: Period between the start of the preparative regimen and day 100 post transplant ]Early onset (before day 100) acute GVHD (including all grades, and stratified by grades) will be assessed according to the Blood and Marrow Transplant Clinical Trials Network Manual version 2, 2005, section 1 using the NIH consensus criteria
- Number of patients with Chronic GVHD including overlap syndrome [ Time Frame: Period between the start of the preparative regimen and year 5 post-transplant. ]Chronic GVHD including overlap syndrome, will be assessed according to the 2014 NIH consensus criteria.
- Number of patients with other Infections [ Time Frame: Period between the start of the preparative regimen and day 28 post transplant ]Other Infections will be defined in accordance with the Blood and Marrow Transplant Clinical Trials Network Manual of Procedures
- Number of patients with relapse free survival at 1 year [ Time Frame: Period between the start of the preparative regimen and year 1 post-transplant. ]Survival without relapse of underlying malignancy.
- Overall number of patients survived at 1 year [ Time Frame: Period between the start of the preparative regimen and year 1 post-transplant. ]Survival with or without relapse of underlying malignancy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529825
|Contact: Chanta Whitlow, MPA, CCRP||404-785-0696||Chanta.Whitlow@choa.org|
|United States, Georgia|
|Children's Healthcare of Atlanta||Recruiting|
|Atlanta, Georgia, United States, 30322|
|Contact: Chanta Whitlow, MPA, CCRP 404-785-0696 email@example.com|
|Principal Investigator:||Muna Qayed, MD MSc||Emory University|